| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococcus spp. (coagulase-negative) |
>0.06 |
>16 |
≤0.03 － >16 |
Cefdinir (Omnicef, Cefdiel)  |
267 |
| Staphylococcus spp. (coagulase-negative) |
>0.06 |
>16 |
0.03 － >16 |
Telithromycin (HMR 3647, RU-66647, Ketek) |
496 |
| Staphylococcus spp. (coagulase-negative) |
0.25 |
0.5 |
≤0.12 － 1 |
Quinupristin/Dalfopristin (Synercid) |
496 |
| Staphylococcus spp. (coagulase-negative) |
>0.25 |
>8 |
0.12 － >8 |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
496 |
| Staphylococcus spp. (coagulase-negative) |
>0.25 |
>16 |
≤0.25 － >16 |
Clindamycin (Cleocin) |
496 |
| Staphylococcus spp. (coagulase-negative) |
>0.5 |
>32 |
≤0.12 － >32 |
Cefuroxime (Kefurox, Zinacef) |
267 |
| Staphylococcus spp. (coagulase-negative) |
>1 |
>32 |
≤0.12 － >32 |
Cefaclor (Ceclor, Ceclor CD) |
267 |
| Staphylococcus spp. (coagulase-negative) |
>2 |
>8 |
0.5 － >8 |
Azithromycin (Zithromax, Sumamed, Zitrocin) |
496 |
| Staphylococcus spp. (coagulase-negative) |
>2 |
>32 |
0.5 － >32 |
Ceftriaxone (Rocephin) |
267 |
| Staphylococcus spp. (coagulase-negative) |
>4 |
>4 |
1 － >4 |
Cefixime (Suprax) |
267 |
| Staphylococcus spp. (glycopeptide-intermediate) |
0.5 |
0.5 |
<0.25 － 1 |
Quinupristin/Dalfopristin (Synercid) |
273 |
| Staphylococcus spp. (glycopeptide-intermediate) |
2 |
2 |
0.5 － 4 |
Linezolid (PNU-100766, U-100766, Zyvox) |
273 |
| Staphylococcus spp. (glycopeptide-intermediate) |
4 |
4 |
0.5 － 8 |
CB-181963 (CAB-175) |
273 |
| Staphylococcus spp. (glycopeptide-intermediate) |
4 |
8 |
4 － 8 |
Vancomycin (Vancocyn, Lyphocin) |
273 |
| Staphylococcus spp. (methicillin-resistant) |
2 |
4 |
2 － 4 |
Vancomycin (Vancocyn, Lyphocin) |
13 |
| Staphylococcus spp. (meticillin-resistant) |
- |
- |
0.004 － 1 |
Daptomycin (Cubicin) |
1261 |
| Staphylococcus spp. (meticillin-resistant) |
- |
- |
0.25 － 4 |
Vancomycin (Vancocyn, Lyphocin) |
1261 |
| Staphylococcus spp. (serogroup C) |
≤0.12 |
≤0.12 |
≤0.12 － 4 |
Telithromycin (HMR 3647, RU-66647, Ketek) |
18 |
| Staphylococcus spp. (serogroup C) |
0.12 |
8 |
≤0.12 － >16 |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
18 |
| Staphylococcus spp. (serogroup F) |
≤0.12 |
≤0.12 |
≤0.12 － 4 |
Telithromycin (HMR 3647, RU-66647, Ketek) |
18 |
| Staphylococcus spp. (serogroup F) |
0.12 |
8 |
≤0.12 － >16 |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
18 |
| Staphylococcus spp. (serogroup G) |
≤0.12 |
≤0.12 |
≤0.12 － 4 |
Telithromycin (HMR 3647, RU-66647, Ketek) |
18 |
| Staphylococcus spp. (serogroup G) |
0.12 |
8 |
≤0.12 － >16 |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
18 |
| Staphylococcus spp. (vancomycin-intermediate + includes USA, Europe, and Japan) |
0.5 |
1 |
? － ? |
Linezolid (PNU-100766, U-100766, Zyvox) |
306 |